Estudo da atividade anti-tumoral de abrina em tumor mamário murino e sua influência no sistema imune
Carregando...
Data
2012-04-20
Autores
Matos, Djamile Cordeiro de [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
O termo “câncer” corresponde ao conjunto de cerca de 100 doenças que têm em comum uma divisão celular desordenada invadindo os tecidos e órgãos, podendo metastatisar para outras regiões do corpo. Os tumores de mama e de colo do útero são os tipos mais frequentes no sexo feminino, e as estimativas para 2012, no Brasil, são de 52.680 e 17.540 novos casos, respectivamente. Abrina, obtida de sementes de Abrus precatorius é uma proteína inativadora de ribossomos (RIPs) do tipo 2, compostas por duas cadeias peptídicas, uma apresentando atividade enzimática N-glicosidase e a outra atividade lectínica com afinidade a β-D-galactose. Neste estudo, avaliamos o potencial antitumoral contra o câncer de mama de abrina em um modelo de câncer mamário murino já estabelecido em nosso laboratório, concomitante à avaliação dos efeitos imunológicos do tumor e da proteína testada no animal. Para isso avaliamos a partir dos tumores e células do sistema imunológico retirados dos animais do estudo, o percentual de inibição do crescimento e angiogênese tumorais, o percentual de células imunes e de células apoptóticas no peritôneo e baço, a produção de citocinas e mediadores químicos produzidos pelas células imunes. Com base nos resultados obtidos, observou-se que o tratamento com abrina (7,5μg/kg) apresentou eficácia similar ao da droga padrão pois apresentou infiltrado inflamatório misto dentro tumor, percentuais de inibição de crescimento e de angiogênese tumorais, e de células NK e NKT esplênicas similares ao tratamento padrão (doxorrubicina - 6mg/kg); em contrapartida apresentou menor quantidade de macrófagos peritoneais e células dendríticas esplênicas ativadas, células T CD8+ citotóxicas e células T regs (CD25+Foxp3+), e maior percentual de células T CD4+, maior produção de H2O2, IL- 1β, IL-6 e IL-12 por células peritoneais...
The word Cancer corresponds to a group with about 100 diseases which have in common a disordered cell division, resulting in tissues and organs invasion and also metastasis to other body regions. Breast and cervix tumours are the most common type in women and, in Brazil, the estimates for 2012 are of 52,680 and 17,540 new cases respectively. Abrin is obtained from Abrus precatorius seeds being type 2 ribosome inactivating protein (RIP) composed of two peptide chains, one of them possessing N-glycosylase enzyme activity and the other a lectinic activity with affinity for β-D-galactose. In the present work, the antitumour potencial of abrin against breast cancer was evaluated employing a murine breast cancer model already established in our laboratory and concomitantly determining the immunologic effects of the tumour and the protein in mice. From tumours and immune cells isolated from mice belonging to the different experimental groups, the tumour growth inhibition rate and angiogenesis were determined, the percentage of immune and apoptotic cells in the peritoneum and spleen, and also the production of immunologic mediators by immune cells. Based on the results it was found that treatment with abrin (7.5μg/kg) was as effective as the standard drug (doxorubicin - 6 mg/kg) considering that inflammatory tumour infiltrate, tumour growth inhibition and angiogenesis rate, as well as splenic NK and NKT cells percentage were similar. However, abrin-treated animals had a lower percentage of cytotoxic CD8+ and Treg (CD25+Foxp3+) cells as well as activated peritoneal macrophages and splenic dendritic cells accompanied by a higher percentage of CD4+ T cells and increased production of H2O2, IL-1β, IL-6 and Il-12 by peritoneal macrophages and IL-10, IFNγ and TGF-β by splenic lymphocytes. Moreover, abrin-treated animals presented a higher percentage... (Complete abstract click electronic access below)
The word Cancer corresponds to a group with about 100 diseases which have in common a disordered cell division, resulting in tissues and organs invasion and also metastasis to other body regions. Breast and cervix tumours are the most common type in women and, in Brazil, the estimates for 2012 are of 52,680 and 17,540 new cases respectively. Abrin is obtained from Abrus precatorius seeds being type 2 ribosome inactivating protein (RIP) composed of two peptide chains, one of them possessing N-glycosylase enzyme activity and the other a lectinic activity with affinity for β-D-galactose. In the present work, the antitumour potencial of abrin against breast cancer was evaluated employing a murine breast cancer model already established in our laboratory and concomitantly determining the immunologic effects of the tumour and the protein in mice. From tumours and immune cells isolated from mice belonging to the different experimental groups, the tumour growth inhibition rate and angiogenesis were determined, the percentage of immune and apoptotic cells in the peritoneum and spleen, and also the production of immunologic mediators by immune cells. Based on the results it was found that treatment with abrin (7.5μg/kg) was as effective as the standard drug (doxorubicin - 6 mg/kg) considering that inflammatory tumour infiltrate, tumour growth inhibition and angiogenesis rate, as well as splenic NK and NKT cells percentage were similar. However, abrin-treated animals had a lower percentage of cytotoxic CD8+ and Treg (CD25+Foxp3+) cells as well as activated peritoneal macrophages and splenic dendritic cells accompanied by a higher percentage of CD4+ T cells and increased production of H2O2, IL-1β, IL-6 and Il-12 by peritoneal macrophages and IL-10, IFNγ and TGF-β by splenic lymphocytes. Moreover, abrin-treated animals presented a higher percentage... (Complete abstract click electronic access below)
Descrição
Palavras-chave
Mamas - Cancer, Citocinas, Apoptose, Ribossomos, Tumores - Aspectos imunológicos, Doxorrubicina, Galactose, Apoptosis
Como citar
MATOS, Djamile Cordeiro de. Estudo da atividade anti-tumoral de abrina em tumor mamário murino e sua influência no sistema imune. 2012. 114 f. Tese (doutorado) - Universidade Estadual Paulista, Faculdade de Ciências Farmacêuticas, 2012.